Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
Kingboard Holdings Shares Surge After HK$11.77 Billion Block Trade to Expand PCB and AI Supply Chain Business 
TD Bank Expands Employee Monitoring Software to Boost Productivity Amid Privacy Concerns 
John Jumper Leaves Google DeepMind for Anthropic Amid Intensifying AI Talent Race 
Trump Administration Delays DeepSeek and CXMT Trade Blacklist Designations Amid U.S.-China Tensions 
Apple Signals Product Price Hikes Amid Rising Memory Chip Costs 
Hyundai to Acquire SoftBank’s Remaining Boston Dynamics Stake for $325 Million 
SpaceX Stock Slides After IPO Rally as Valuation Concerns Grow 
Meta Seeks Legal Shield From Child-Harm Lawsuits Amid KOSA Talks 
Qantas Unveils Wellness-Focused Nonstop Sydney-London Flights to Reduce Jet Lag 
Samsung Gains Interest from BYD, Google, AMD as AI Chip Demand Strains TSMC Capacity 
Carro Expands Into Australia With Acquisition of Used-Car Platform CarPlace 
Obayashi to Acquire Multiplex in $526M Expansion Deal 
BHP Shares Fall as Jansen Potash Project Costs Surge 
SK Hynix Shares Hit Record High After Shipping Next-Generation HBM4E AI Memory Samples 
SoftBank Shares Drop as OpenAI Losses and Rising Costs Spark Investor Concerns 
US-Iran De-Escalation Shifts Washington’s Focus to AI Regulation and Crypto Legislation 
NEW YORK, Jan. 14, 2016 (GLOBE NEWSWIRE) -- Microlin Bio, Inc., a development stage biotechnology company focused on the development of microRNA based therapeutics for cancer, today announced the change of its trading symbol from AMIB to MICB. The change will take effect on January 14, 2016.
The new trading symbol, which is more closely aligned with the Company’s name, is intended to strengthen the Microlin Bio brand and increase its profile within the investment community.
Beginning January 14, 2016 all information, including stock trading, SEC filings, and market data related to Microlin Bio, will be reported under the new ticker symbol, “MICB.” The CUSIP for company’s common stock will remain unchanged. Outstanding stock certificates are not affected by the symbol change and will not need to be exchanged.
About microRNA
MicroRNAs are recently discovered naturally occurring RNA molecules (composed of 19 to 25 nucleotides) that do not encode proteins but instead regulate gene expression and various biological pathways. The improper balance of microRNAs are linked to many diseases, including cancer. As such, replacement or inhibition of deregulated microRNAs may act as a potent means to treat cancers.
About Microlin Bio, Inc.
Microlin Bio, Inc. is a development stage biotechnology company focused primarily on the development of microRNA based therapeutics to treat cancer from technologies licensed from Ohio State University. This includes over 138 pending patent applications and 132 granted patents covering numerous microRNAs. For more information, please visit www.microlinbio.com.
Microlin Bio Forward-Looking Statements
This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995, regarding the research, development and commercialization of pharmaceutical products. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements in the press release should be evaluated together with the many uncertainties that affect Microlin Bio’s business and Microlin Bio undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.
The Ruth Group Lee Roth (investors) [email protected] (646) 536-7012 Ashley Brown (media) [email protected] (646)536-7002
